Elanix Biotechnologies AG

DUSE:ELN Stock Report

Market Cap: €428.3k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Elanix Biotechnologies Balance Sheet Health

Financial Health criteria checks 0/6

Insufficient data to determine the health of Elanix Biotechnologies

Key information

n/a

Debt to equity ratio

n/a

Debt

Interest coverage ration/a
Cashn/a
Equityn/a
Total liabilitiesn/a
Total assetsn/a

Recent financial health updates

No updates

Recent updates

No updates

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if ELN's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if ELN's short term assets cover its long term liabilities.


Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate ELN's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if ELN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if ELN's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if ELN's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies